Drugs / GD2, PSMA and CD276 CAR-T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT04637503 | Jun 2026 → Dec 2029 expected | neuroblastoma | Shenzhen Geno-Immune Medical Institute | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GD2, PSMA and CD276 CAR-T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04637503 ↗ |
| Known as | 4SCAR-T | “The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in...” NCT04637503 ↗ |
| Action | Deplete | “designed to kill tumor cells through specific recognition of GD2, PSMA and CD276” NCT04637503 ↗ |
| Modality | Cell therapy | “Gene-modified T cells” NCT04637503 ↗ |
| Route | Intravenous | “via IV” NCT04637503 ↗ |